PIK3CA and head and neck squamous cell carcinoma: Recently, buparlisib combined with paclitaxel showed improved efficacy in the treatment of R/M SCCHN patients over paclitaxel alone, suggesting the importance of PI3K inhibition.9 We therefore conducted a Phase 2 study of buparlisib in R/M SCCHN.